Startup profile for Orbital Therapeutics: what they do, why they are interesting, stage (acquired), industries, and links to our funding articles. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker Logo

Venture Capital Tracker

Startup profile · funding coverage

Orbital Therapeutics

Orbital Therapeutics raised a $270M Series A in 2023 to build next-generation RNA medicine platforms.

Stage

acquired

Status

acquired

Coverage

full

Why Orbital Therapeutics is interesting

One of 2023’s largest biotech Series A rounds — ARCH led the Cambridge RNA platform play with a16z Bio + Health as an initial backer.

Key facts

  • Series A (Apr 2023): $270M led by ARCH Venture Partners; a16z Bio + Health participated (Businesswire)

Investors in our directory

Funds linked from Orbital Therapeutics's profile — open a fund page for stage focus and related deal articles.

Andreessen HorowitzARCH Venture Partners

Industries

Healthtech Biotech & Life Sciences

Industry hub pages are rolling out from our fund-derived baseline taxonomy.

Related funding articles

Venture Capital Tracker pieces that cover Orbital Therapeutics's financing or category context.

All startups Funding news

Last updated: 2026-07-24